Revenue
No reported data
Dermata Therapeutics, Inc. (DRMA)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $2.9M | $8.2M | $4.1M | $5.7M | $3.5M | $1.6M |
| Operating expenses | $7.8M | $12.5M | $8.0M | $9.7M | $7.9M | $3.2M |
| Operating income | −$7.8M | −$12.5M | −$8.0M | −$9.7M | −$7.9M | −$3.2M |
| EBITDAderived | — | — | — | — | −$7.9M | −$3.2M |
| Net income | −$7.6M | −$12.3M | −$7.8M | −$9.6M | −$7.9M | −$3.2M |
| Basic EPSper diluted share | -$8.16 | -$80.32 | -$39.99 | -$13.92 | -$2.43 | -$1.69 |
| Diluted EPSper diluted share | -$8.16 | -$80.32 | -$39.99 | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 16, 2026Form 4 | Scott Kathleen D.Director | SellCommon Stock | 11 | $1.19 | $13.09 | 0 |
| Feb 17, 2026Form 4 | Bedoya-Toro Munera Maria ESVP, Regulatory Affairs | BuyCommon Stock | 1.0K | $1.27 | $1.3K | 1.0K |